BURLINGAME, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage
biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that
it will host an R&D Day on Tuesday, July 11, 2017, in New York City and provide a live webcast starting at 9:00 a.m. ET.
The event will focus on the adenosine pathway in immuno-oncology and its potential to address the limitations of existing
agents. Speakers will include:
- Jonathan D. Powell, M.D., Ph.D., of Johns Hopkins University
- Lawrence Fong, M.D., of the University of California, San Francisco
- Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center
- Richard Miller, M.D., Corvus co-founder, president and CEO
R&D Day Webcast and Conference Call Details
Event Title: R&D Day Update – The Adenosine Pathway: Extending the Reach of Cancer Immunotherapy
Date: Tuesday, July 11, 2017
Time: 9:00 a.m. – 12:00 p.m. ET
Webcast: The live webcast and slide presentation can be accessed at https://event.webcasts.com/starthere.jsp?ei=1137880
An archive of the webcast will be available in the Investors section of the Company’s website for 30 days following the event.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small
molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial
immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to
disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is
a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients
with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and
in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of
the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more
information, visit www.corvuspharma.com.
Tecentriq® (atezolizumab) is a registered trademark of Genentech.
Corvus Contact: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 LLea@corvuspharma.com Media Contact: Megan McCormick Pure Communications +1-858-617-0774 mmccormick@purecommunications.com
